You choose, we deliver
If you are interested in this story, you might be interested in others from The Journal Gazette. Go to www.journalgazette.net/newsletter and pick the subjects you care most about. We'll deliver your customized daily news report at 3 a.m. Fort Wayne time, right to your email.

Health

  • Lutheran Life Villages to merge home-care division
    Lutheran Life Villages has announced plans to merge its home care division with Birchwood Inc., a facility that provides day care to people with dementia, giving caregivers respite and time for other responsibilities.
  • Parkview, Wabash hospital to pursue affiliation
    Parkview Health and Wabash County Hospital said today they intended to pursue an affiliation agreement, the structure of which is to be defined in the coming months.
  • Pot study finds signs of brain changes
    A small study of casual marijuana smokers has turned up evidence of changes in the brain, a possible sign of trouble ahead, researchers say.
Advertisement

China Rx approval slow: Lilly boss

– China takes eight years longer on average to approve drugs than other major countries and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly & Co. CEO John Lechleiter said.

“This is a drug lag that I hope we are able to close in the coming years, by working with Chinese authorities to speed up the process of doing clinical trials in China,” Lechleiter said last week in an interview in Beijing. The 59-year-old executive is spending the week in China to meet with government officials and business executives as chairman of the industry group Pharmaceutical Research and Manufacturers of America.

Lilly itself aims to conduct simultaneous late-stage tests in China for products such as the experimental diabetes drug dulaglutide, according to Lechleiter. The Indianapolis drugmaker wants to introduce more than a dozen medicines in China in the next five years, including drugs for diabetes and cancer, and aims to keep sales there growing 25 percent as they did last year, he said in March.

Drugmakers are working to expand their offerings in China, the world’s fastest-growing pharmaceuticals market, as revenue drops elsewhere, hurt by expiring patents on blockbusters. Lilly in October said quarterly earnings had missed analyst estimates after generic competition hurt revenue from the schizophrenia treatment Zyprexa, once the company’s top-selling drug.

Lechleiter said “prospects are good” for further expansion of Lilly’s drug-manufacturing operations in China. The company opened a second plant in June this year in the eastern city of Suzhou.

Advertisement